287 related articles for article (PubMed ID: 24892807)
41. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells.
Roberts DJ; Franklin NA; Kingeter LM; Yagita H; Tutt AL; Glennie MJ; Bullock TN
J Immunother; 2010 Oct; 33(8):769-79. PubMed ID: 20842060
[TBL] [Abstract][Full Text] [Related]
42. Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models.
Shin JH; Park HB; Oh YM; Lim DP; Lee JE; Seo HH; Lee SJ; Eom HS; Kim IH; Lee SH; Choi K
Blood; 2012 Jun; 119(24):5678-87. PubMed ID: 22538857
[TBL] [Abstract][Full Text] [Related]
43. Intradermal delivery of STAT3 siRNA to treat melanoma via dissolving microneedles.
Pan J; Ruan W; Qin M; Long Y; Wan T; Yu K; Zhai Y; Wu C; Xu Y
Sci Rep; 2018 Jan; 8(1):1117. PubMed ID: 29348670
[TBL] [Abstract][Full Text] [Related]
44. Delivery of interferons and siRNA targeting STAT3 using lentiviral vectors suppresses the growth of murine melanoma.
Wang X; Liu P; Liu H; Yang W; Liu Z; Zhuo Z; Gao Y
Cancer Gene Ther; 2012 Dec; 19(12):822-7. PubMed ID: 23018621
[TBL] [Abstract][Full Text] [Related]
45. Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice.
Bastaki S; Aravindhan S; Ahmadpour Saheb N; Afsari Kashani M; Evgenievich Dorofeev A; Karoon Kiani F; Jahandideh H; Beigi Dargani F; Aksoun M; Nikkhoo A; Masjedi A; Mahmoodpoor A; Ahmadi M; Dolati S; Namvar Aghdash S; Jadidi-Niaragh F
Life Sci; 2021 Feb; 266():118847. PubMed ID: 33309720
[TBL] [Abstract][Full Text] [Related]
46. Methods for assembling B-cell lymphoma specific and internalizing aptamer-siRNA nanoparticles via the sticky bridge.
Zhou J; Rossi JJ; Shum KT
Methods Mol Biol; 2015; 1297():169-85. PubMed ID: 25896003
[TBL] [Abstract][Full Text] [Related]
47. Bone marrow endothelium-targeted therapeutics for metastatic breast cancer.
Mai J; Huang Y; Mu C; Zhang G; Xu R; Guo X; Xia X; Volk DE; Lokesh GL; Thiviyanathan V; Gorenstein DG; Liu X; Ferrari M; Shen H
J Control Release; 2014 Aug; 187():22-9. PubMed ID: 24818768
[TBL] [Abstract][Full Text] [Related]
48. Expansion of Tumor-Infiltrating CD8
Fernandez-Poma SM; Salas-Benito D; Lozano T; Casares N; Riezu-Boj JI; Mancheño U; Elizalde E; Alignani D; Zubeldia N; Otano I; Conde E; Sarobe P; Lasarte JJ; Hervas-Stubbs S
Cancer Res; 2017 Jul; 77(13):3672-3684. PubMed ID: 28522749
[TBL] [Abstract][Full Text] [Related]
49. Concomitant blockade of A2AR and CTLA-4 by siRNA-loaded polyethylene glycol-chitosan-alginate nanoparticles synergistically enhances antitumor T-cell responses.
Ghasemi-Chaleshtari M; Kiaie SH; Irandoust M; Karami H; Nabi Afjadi M; Ghani S; Aghaei Vanda N; Ghaderi Sede MJ; Ahmadi A; Masjedi A; Hassannia H; Atyabi F; Hojjat-Farsangi M; Namdar A; Ghalamfarsa G; Jadidi-Niaragh F
J Cell Physiol; 2020 Dec; 235(12):10068-10080. PubMed ID: 32488862
[TBL] [Abstract][Full Text] [Related]
50. Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.
Pallandre JR; Brillard E; Créhange G; Radlovic A; Remy-Martin JP; Saas P; Rohrlich PS; Pivot X; Ling X; Tiberghien P; Borg C
J Immunol; 2007 Dec; 179(11):7593-604. PubMed ID: 18025205
[TBL] [Abstract][Full Text] [Related]
51. The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line.
Akiyama Y; Nonomura C; Ashizawa T; Iizuka A; Kondou R; Miyata H; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Asai A; Ito M; Kiyohara Y; Yamaguchi K
Immunol Lett; 2017 Oct; 190():20-25. PubMed ID: 28716484
[TBL] [Abstract][Full Text] [Related]
52. Potent antitumor effects of cell-penetrating peptides targeting STAT3 axis.
Aftabizadeh M; Li YJ; Zhao Q; Zhang C; Ambaye N; Song J; Nagao T; Lahtz C; Fakih M; Ann DK; Yu H; Herrmann A
JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33491667
[TBL] [Abstract][Full Text] [Related]
53. Requirement of Treg-intrinsic CTLA4/PKCη signaling pathway for suppressing tumor immunity.
Pedros C; Canonigo-Balancio AJ; Kong KF; Altman A
JCI Insight; 2017 Dec; 2(23):. PubMed ID: 29212947
[TBL] [Abstract][Full Text] [Related]
54. The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade.
Yamazaki T; Pitt JM; Vétizou M; Marabelle A; Flores C; Rekdal Ø; Kroemer G; Zitvogel L
Cell Death Differ; 2016 Jun; 23(6):1004-15. PubMed ID: 27082453
[TBL] [Abstract][Full Text] [Related]
55. Sonodynamic therapy improves anti‑tumor immune effect by increasing the infiltration of CD8+ T cells and altering tumor blood vessels in murine B16F10 melanoma xenograft.
Peng Y; Jia L; Wang S; Cao W; Zheng J
Oncol Rep; 2018 Oct; 40(4):2163-2170. PubMed ID: 30106435
[TBL] [Abstract][Full Text] [Related]
56. Downregulation of Stat3 in melanoma: reprogramming the immune microenvironment as an anticancer therapeutic strategy.
Emeagi PU; Maenhout S; Dang N; Heirman C; Thielemans K; Breckpot K
Gene Ther; 2013 Nov; 20(11):1085-92. PubMed ID: 23804077
[TBL] [Abstract][Full Text] [Related]
57. Plasmid-based STAT3-siRNA efficiently inhibits breast tumor growth and metastasis in mice.
Dai L; Cheng L; Zhang X; Jiang Q; Zhang S; Wang S; Li Y; Chen X; DU T; Yang Y; Tian H; Fan P; Yan N; Dai L; Wei Y; Deng H
Neoplasma; 2011; 58(6):538-47. PubMed ID: 21895408
[TBL] [Abstract][Full Text] [Related]
58. Th17 cells inhibit CD8
Wang D; Yu W; Lian J; Wu Q; Liu S; Yang L; Li F; Huang L; Chen X; Zhang Z; Li A; Liu J; Sun Z; Wang J; Yuan W; Zhang Y
J Hematol Oncol; 2020 Jun; 13(1):68. PubMed ID: 32503584
[TBL] [Abstract][Full Text] [Related]
59. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
Moran AE; Polesso F; Weinberg AD
J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
[TBL] [Abstract][Full Text] [Related]
60. Depletion of CD4(+)CD25(high) regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy.
Xu L; Xu W; Jiang Z; Zhang F; Chu Y; Xiong S
Cancer Biol Ther; 2009 Jan; 8(1):66-72. PubMed ID: 19029829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
